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ABSTRACT 
 The anion channel cystic fibrosis transmembrane conductance regulator (CFTR) is a 
unique ATP-binding cassette (ABC) transporter.  CFTR plays a pivotal role in transepithelial 
ion transport as its dysfunction in the genetic disease cystic fibrosis (CF) dramatically 
demonstrates.  Phylogenetic analysis suggests that CFTR first appeared in aquatic vertebrates 
fulfilling important roles in osmosensing and organ development.  Here, we review selectively 
knowledge of CFTR structure, function and pharmacology, gleaned from cross-species 
comparative studies of recombinant CFTR proteins, including CFTR chimeras.  The data argue 
that subtle changes in CFTR structure can impact strongly on channel function and the action 
of CF mutations. 
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ABBREVIATIONS 
ABC transporter, ATP-binding cassette transporter; CF, cystic fibrosis; CFTR, cystic 
fibrosis transmembrane conductance regulator; ECL, extracellular loop; ICL, intracellular loop; 
MSD, membrane-spanning domain; NBD, nucleotide-binding domain; RD, regulatory domain 
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INTRODUCTION 
The life-shortening genetic disease cystic fibrosis (CF) is caused by mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) [1].  CFTR is a unique member 
of the ATP-binding cassette (ABC) transporter superfamily (ABCC7) that functions as an 
anion-selective channel [2].  CFTR is found primarily in the apical membrane of epithelial cells 
lining ducts and tubes, where it plays a key role in epithelial fluid and electrolyte transport and 
the maintenance of cellular homeostasis [3].  Loss of CFTR function in CF causes the blockage 
of ducts and tubes by thick, tenacious mucus, leading to the development of diverse organ 
pathologies (e.g. chronic lung disease, exocrine pancreatic failure, meconium ileus (blockage 
of the intestine in neonates), male infertility and salty sweat) [3,4]. 
 
To date, more than 2,000 CF-associated mutations have been identified within the 
CFTR gene (http://www.genet.sickkids.on.ca/app).  As summarised in Figure 1A, CF-
associated mutations are assigned to one of six different classes according to their impact on 
CFTR production, processing, plasma membrane stability and channel function (for review, see 
Ref [5]).  While some CF-associated mutations disrupt CFTR function by a single mechanism, 
frequently they have complex effects on CFTR expression and function.  For example, the most 
common CF mutant, F508del-CFTR is assigned to class II (defective processing), but it also 
exhibits defects characteristic of classes III (defective channel regulation) and VI (reduced 
protein stability) [5].  This highlights the challenge of elucidating mechanisms of dysfunction 
to inform the development of mutation-specific therapies for CF. 
 
Current therapy for CF treats disease symptoms.  To date, the only mutation-specific 
therapy approved for patient use is ivacaftor, a small molecule that potentiates CFTR channel 
gating, developed by Vertex Pharmaceuticals (Boston, USA) with support from Cystic Fibrosis 
Foundation (Bethesda, USA) [6,7].  However, use of ivacaftor is restricted to a small cohort of 
CF patients carrying class III mutations affecting CFTR channel gating (e.g. G551D-CFTR 
[8,9]) [4].  In addition to potentiation of channel gating, mutation-specific therapy for F508del-
CFTR must correct defective protein delivery to and stability at the plasma membrane [5,10].  
Clinical trials of combination therapy (ivacaftor and lumacaftor (Vertex Pharmaceuticals), a 
small molecule that corrects the F508del-CFTR processing defect) were completed in 2014 and 
are now being evaluated for regulatory approval [11].  Because the F508del mutation affects 
CFTR folding in multiple ways (e.g. [12,13]), combinations of CFTR correctors will likely be 
required to fully restore CFTR function. 
 
One barrier to the development of mutation-specific therapies for CF is the lack of an 
atomic-resolution structure of the entire CFTR protein.  In its absence, molecular models of 
CFTR have been constructed using the crystal structures of related ABC transporters (e.g. 
Sav1866 [14]) as templates [15,16].  Figure 1B shows CFTR in a nucleotide-bound outward-
facing configuration.  In this configuration, the nucleotide-binding domains (NBDs) form a 
head-to-tail dimer stabilised by ATP binding to two ATP-binding sites (site 1, non-hydrolytic; 
site 2, hydrolytic) located at the dimer interface.  By contrast, the membrane-spanning domains 
(MSDs) form an asymmetric hour-glass with a deep wide intracellular vestibule and a shallow 
wide extracellular vestibule separated by a constriction located towards the extracellular end of 
the pore.  Functional evidence argues that the pore constriction not only determines the anion 
selectivity of CFTR [17], which follows a lyotropic series [18], but is also the location of a gate 
[19].  Of note, this gate location supports the degraded ABC transporter model of CFTR 
function [20], which argues that CFTR evolved from a double-gated ancestral ABC transporter 
by atrophy of one gate.  Communication between the NBDs and MSDs is mediated by four 
coupling helices, located at the tips of four intracellular loops (ICLs), long -helical extensions 
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of transmembrane segments in MSD1 and MSD2 [15,16].  A unique feature of CFTR is its 
regulatory domain (RD) (Fig. 1B), an intrinsically disordered protein segment, distinguished 
by multiple consensus phosphorylation sites, which interacts with all intracellular regions of 
CFTR [21].  RD phosphorylation not only relieves steric inhibition of NBD1:NBD2 
dimerisation by the RD, but also stimulates the interaction of ATP with the ATP-binding sites 
(for review, see Ref [21]).  ATP binding and hydrolysis at site 2 then drives cycles of 
NBD1:NBD2 dimer assembly and disassembly [2].  Movement of the NBD1:NBD2 dimer 
initiates a wave of conformational change, which moves through the ICLs to the MSDs to gate 
the pore constriction and hence, control anion flow [22]. 
 
EMERGENCE OF CFTR: A Cl- CHANNEL FOR OSMOSENSING AND ORGAN 
DEVELOPMENT 
Following the identification of CFTR and the cloning of its cDNA [1], CFTR 
homologues have been discovered in a diverse range of vertebrates (Figure 2 and 
Supplementary Material Table 1) [23].  It is unclear when CFTR first appeared within the 
phylogenetic tree.  However, molecular evolution studies, which exploit the RD as a unique 
feature of CFTR, argue that CFTR emerged early in the development of gnathostomes (jawed 
vertebrates) and is absent among other chordate classes (e.g. lamprey and hagfish) [24].  
Interestingly, these studies argue that the RD originated from non-coding intronic sequences, 
providing an explanation for its intrinsically disordered structure [24].  Of note, no CFTR 
homologue has been confirmed in the model invertebrate organisms Drosophila melanogaster 
and Caenorhabditis elegans, in contrast to sulphonylurea receptors and multidrug resistance-
associated proteins [25,26], both close relatives of CFTR in the C subdivision of the ABC 
transporter superfamily.  The identification of CFTR expression in teleost fish such as Takifugu 
rubripes [27], Fundulus heteroclitus (killifish) [28] and two distinct homologues in the 
tetraploid Atlantic Salmon Salmo salar [23] suggests that CFTR might have evolved in aquatic 
vertebrates to play a key role in osmoregulation.  Indeed, studies of mitochondrion-rich cells in 
the gills and opercular epithelium of killifish demonstrate that CFTR is the apical membrane 
Cl- channel in these osmosensing ion transporting epithelia [29].  Interestingly, in 
mitochondrion-rich cells of killifish, the tyrosine kinase focal adhesion kinase integrates both 
cAMP-dependent and osmotically-mediated cAMP-independent intracellular signals to 
regulate CFTR [30].  Changes in osmolarity exert complex effects on CFTR expression and 
function, initially altering CFTR regulation and protein recycling at the apical membrane of 
mitochondrion-rich cells, but later modifying gene expression [30,31]. 
 
 While other anion channels also likely play a role in morphogenesis, studies of the 
model organism Danio rerio (zebrafish) suggest an important role for CFTR in organ 
development by driving lumen expansion during the formation of ducts and tubes [32].  For 
example, loss of Cse1l (chromosome segregation 1-like), a negative regulator of CFTR-
mediated transepithelial ion transport, leads to a striking expansion of the intestinal lumen in 
zebrafish larvae [33].  Conversely, CFTR knockout in zebrafish embryos prevents lumen 
formation in Kupffer’s vesicle, which specifies the left-right body axis [34].  The absence of 
left-right symmetry defects in CF patients argues that CFTR, itself, does not determine organ 
location in humans.  Nevertheless, there is some evidence for developmental defects in CF (e.g. 
tracheal narrowing caused by altered smooth muscle function [35]).  While CFTR loss does not 
prevent lumen formation in zebrafish pancreas [36], the role of CFTR in duct and tube 
formation, particularly the vas deferens, the duct most sensitive to CFTR loss [37], should be 
examined further. 
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SPECIES DIFFERENCES IN CFTR CONDUCTANCE, GATING AND 
PHARMACOLOGY 
To date, the single-channel behaviour of only a limited number of recombinant CFTR 
homologues has been investigated (spiny dogfish [shark], [38]; frog [39]; mouse, [40]; chicken, 
[41]; bushtail possum, [42]; rabbit, [41]; sheep, [43]; pig, [44]).  In all cases, expression of 
recombinant CFTR generated Cl--selective channels regulated by cAMP-dependent 
phosphorylation and intracellular ATP.  However, frequently studies of CFTR homologues 
have revealed surprising differences in single-channel behaviour, which inform understanding 
of structure-function relationships.  Here, we selectively review the literature. 
 
Shortly after the identification of the CFTR gene, mouse models of CF emerged, which 
highlighted interspecies differences in disease phenotype (for review, see Ref [45]).  Amino 
acid sequence analysis reveals that murine CFTR differs noticeably from human CFTR, 
possessing an amino acid sequence identity similar to that of Xenopus CFTR (Fig. 2 and SM 
Table 1).  The first single-channel recordings of murine CFTR suggested that its channel 
activity is greatly reduced compared to that of human CFTR [40].  These recordings identified 
the reduced single-channel current amplitude of murine CFTR and the short-lived sojourns to 
its full open-state (Fig. 3A, left and B).  However, they failed to detect a tiny, long lived 
subconductance state of murine CFTR, which was only detected following inconsistencies 
between iodide efflux and single-channel studies of CFTR modulators and required heavy 
filtering for its resolution [46] (Fig. 3A, right).  Thus, the gating behaviour of murine CFTR is 
characterised by prolonged openings to a tiny subconductance state (O1) and only brief transits 
to the full open state (O2) [46] (Fig. 3A).  As a result, the open probability of murine O1 is 
greater than that of human CFTR, whereas that of murine O2 is dramatically reduced [46] (Fig. 
3C). 
 
Interestingly, AMP-PNP and pyrophosphate, two agents that potentiate robustly human 
CFTR channel gating do not augment the activity of murine CFTR [40].  Consistent with these 
data, a number of potentiators (e.g. VRT-532, NPPB-AM and ivacaftor) which augment 
robustly human CFTR channel gating have little or no effect on murine CFTR [6,47].  While 
these results argue that CF mice are unsuitable for testing CFTR potentiators, this is not the 
case for CFTR correctors.  For example, the off-patent drug glafenine improved the trafficking 
of murine F508del-CFTR ex vivo and partially restored salivary secretion in vivo in CF mice 
with the F508del mutation, without causing adverse effects [48].  These data argue that CF mice 
have a role to play in evaluating rational new therapies for CF. 
 
 Species-dependent differences in CFTR inhibition by open-channel blockers and 
allosteric inhibitors have also been identified.  First, shark CFTR is insensitive to the 
thiazolidinone CFTRinh-172, an allosteric inhibitor that modulates channel gating [49].  Second, 
porcine CFTR is unaffected by the sulphonylurea drug glibenclamide, which occludes the 
intracellular vestibule of the CFTR pore [49].  Third, murine CFTR is insensitive to the glycine 
hydrazide GlyH-101, which obstructs the extracellular vestibule of the CFTR pore [50].  To 
explain these differences in channel inhibition, Stahl et al. [49] postulated that subtle 
differences in the three-dimensional structure of the CFTR pore and the local environment (e.g. 
hydrophobicity and charge) in the vicinity of drug-binding sites might be responsible.  In future 
studies, these differences might be exploited to identify drug-binding sites on CFTR. 
 
Towards the development of a sheep model of CF, we recently investigated with Ann 
Harris (Northwestern University Feinberg School of Medicine) the single-channel behaviour of 
ovine CFTR, a CFTR homologue with a high degree of sequence identity to human CFTR (Fig. 
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2 and SM Table 1).  As demonstrated in Figure 3, ovine CFTR is noticeably more active than 
human CFTR.  The reasons are three-fold: (i) the single-channel conductance of ovine CFTR 
is greater than that of human CFTR; (ii) the open probability of ovine CFTR is larger than that 
of human CFTR and (iii) ATP more strongly stimulates ovine CFTR channel gating [43].  For 
human CFTR, ATP predominantly regulates channel gating by increasing the frequency of 
channel openings [2].  However, in ovine CFTR, ATP accelerates the rate of channel opening, 
while simultaneously slowing the rate of channel closure [43].  Based on the energetic coupling 
model of CFTR channel gating [51], one possible explanation for the single-channel behaviour 
of ovine CFTR is that its gating cycle might be uncoupled from its ATP hydrolysis cycle.  With 
Isabelle Callebaut (IMPMC, Sorbonne Universités), we sought structural explanations for the 
single-channel behaviour of ovine CFTR using Sav1866-based molecular models of CFTR [16] 
(Fig. 1B).  This analysis revealed no clear differences between human and ovine CFTR within 
critical motifs in the MSDs and NBDs [43].  Instead, amino acid sequence differences were 
mostly confined to regions with known (or predicted) regulatory roles and characterised by the 
presence of additional serine and threonine residues in ovine CFTR [43].  In the future, it will 
be interesting to explore the regulation of ovine CFTR by protein kinases and phosphatases. 
 
 Variation in experimental conditions hampers data comparison between different 
studies of CFTR homologues.  Nevertheless, data suggest that single-channel conductance 
varies between species, decreasing in the rank order chicken >> ovine ≥ rabbit ≥ Xenopus > 
human ≥ possum > porcine > murine ≥ shark [38-44,52].  Figure 3D explores the relationship 
between single-channel conductance and mean body temperature for endotherms.  These data 
raise the interesting possibility that metabolic activity might influence CFTR behaviour.  Future 
studies should investigate this possibility by studying CFTR homologues under identical 
experimental conditions. 
 
SPECIES DIFFERENCES AS A TOOL TO UNDERSTAND CFTR STRUCTURE AND 
FUNCTION 
 While site-directed mutations are the method of choice to explore structure-function 
relationships, studies of CFTR chimeras have an important role to play.  For example, studies 
of human-Xenopus CFTR chimeras provided early evidence that the first extracellular loop 
(ECL1) is an important determinant of CFTR channel gating.  Single-channel studies revealed 
that the chimera hX1-6 containing MSD1 of Xenopus CFTR on a human CFTR background 
had an unusual pattern of channel gating distinct from the bursting pattern exhibited by human 
and Xenopus CFTR [39].  Recognising that the gating pattern of hX1-6 resembled the CF 
mutant R117H-CFTR [53], Price et al. [39] focused on sequence differences in the ECLs.  
Substitution of human ECL1, but not human ECL3, restored the bursting pattern of channel 
gating to hX1-6 [39].  Interestingly, guided by a molecular model of CFTR, Cui et al. [54] 
demonstrated that three charged residues in ECL1 (D110, E116 and R117), conserved across 
species, stabilise the conformation of the CFTR pore by forming salt bridges with nearby 
charged residues in the extracellular vestibule. 
 
 Using homologous recombination to generate a library of human-murine CFTR 
chimeras exchanging human NBD and RD sequences with the corresponding regions of murine 
CFTR, we demonstrated that NBD1 and NBD2 together determine the prolonged duration of 
the subconductance state of murine CFTR [55].  Because human-murine CFTR chimeras with 
one human and one murine NBD were functional [55], channel gating, albeit suboptimal, is 
possible when NBDs from two homologues are mixed.  Moreover, studies of the processing of 
human-murine CFTR chimeras demonstrated that with two exceptions, replacement of human 
sequences with their murine equivalents had no adverse effects on CFTR folding [56].  Taken 
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together the data raise the interesting possibility of using chimeric channels with CFTR’s MSDs 
to investigate the gating cycle of NBDs from other ABC transporters. 
 
SPECIES DIFFERENCES AS A TOOL TO INVESTIGATE CF-ASSOCIATED 
MUTATIONS 
 In marked contrast to its impact on human CFTR, the F508del mutation has variable 
effects on the processing of CFTR homologues ranging from less severe in mammalian 
homologues (e.g. porcine and murine) to almost no effect in non-mammalian species (e.g. 
chicken and frog) [41,44].  Moreover, F508del chicken CFTR exhibits marked thermostability, 
remaining active at physiological temperatures, unlike F508del human CFTR, which 
deactivates promptly [41].  Hypothesizing that structural differences between human and 
chicken CFTR account for the thermostability of F508del chicken CFTR, Aleksandrov et al. 
[41] demonstrated that the F508del revertant I539T and four proline residues at key positions 
within NBD1 (S422P, S434P, S492P and A534P) were responsible for rescuing the processing, 
plasma membrane stability and function of human CFTR.  These data argue that correction of 
NBD1 structure is sufficient to suppress fully the deleterious effects of the F508del mutation 
on human CFTR.  However, Ostedgaard et al. [44] interpreted species-dependent effects of the 
F508del mutation on CFTR processing and channel function to suggest that these defects have 
different causes.  In support of this idea, studies of human-murine CFTR chimeras revealed that 
maturation of F508del-CFTR requires NBD1, whereas rescue of F508del-CFTR channel gating 
necessitates NBD1-MSD2 interactions [57].  Consistent with the ideas of Ostedgaard et al. [44], 
other studies (e.g. [12,13]) demonstrate that correction of NBD1 folding and the interaction of 
NBD1 with ICL4 are required to suppress fully the defective protein processing and channel 
function of F508del-CFTR. 
 
CONCLUSIONS 
 Cross-species comparative studies are a powerful approach to investigate the 
physiological role of CFTR and its dysfunction in disease.  They have the potential to reveal 
surprising differences in channel function despite high degrees of shared amino acid sequence 
identity.  Testing small molecules on heterologously expressed CFTR homologues informs 
proof of principle studies in animal models of disease, while chimeric CFTR constructs provide 
exciting opportunities to identify drug-binding sites on CFTR.  Future studies should confront 
the challenge of investigating the single-channel properties of endogenous CFTR Cl- channels 
in native epithelial cells.  Ultimately, such studies in humans have the potential to illuminate 
genotype-phenotype-CFTR function relationships.  We should not shy from this challenge. 
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FIGURE LEGENDS 
Figure 1: Molecular mechanisms of CFTR dysfunction in CF  (A) Classification of CF-
associated mutations based on their effects on CFTR production, maturation, plasma membrane 
stability and function.  Class I mutations, defective protein production; class II mutations, 
defective protein processing; class III mutations, defective channel regulation; class IV 
mutations, defective channel conduction; class V mutations, reduced protein synthesis and class 
VI mutations, reduced protein stability.  (B) Homology model of CFTR based upon 
Staphylococcus aureus Sav1866 [14] in an ATP-bound outward-facing configuration [58].  
Membrane-spanning domain 1 (MSD1) is coloured cyan; MSD2, green, NBD1, violet; NBD2, 
purple; RD, grey and ATP molecules, yellow.  The position of the plasma membrane is 
indicated with Int. and Ext. denoting the intra- and extracellular sides of the membrane, 
respectively.  Reproduced, with permission, from Ref [58]. 
 
Figure 2: Phylogenetic relationship of CFTR  The cladogram was constructed following 
ClustalO alignment of experimentally-derived and predicted whole-protein CFTR amino acid 
sequences.  With the exception of mouse and rat [59], this cladogram largely reflects the 
evolutionary tree of the listed species.  For further information, see Supplementary Material 
Table 1. 
 
Figure 3: The single-channel behaviour of CFTR homologues  (A) Representative single-
channel recordings of human, ovine and murine CFTR in excised inside-out membrane patches 
from CHO cells expressing the indicated CFTR variants acquired using the experimental 
conditions described in Ref [43].  The closed-channel state (C), the subconductance state of 
murine CFTR (O1) and the full-open state (human and ovine CFTR, O; murine, O2) are 
indicated by dotted lines.  Traces on the left were filtered at 500 Hz, whereas the 2-s portions 
indicated by bars shown on an expanded time scale to the right were filtered at 50 Hz.  (B, C) 
Single-channel current amplitude (i) and open probability (Po) of human (h), ovine (o) and 
murine (m) CFTR for the experimental conditions described in Ref [43], except murine CFTR, 
which was studied with ATP (0.3 mM) in the intracellular solution.  Data are means ± SEM 
(human, n = 10, ovine, n = 24, murine, n = 5); *, P < 0.05 vs. human CFTR.  Data were 
originally published in Ref [55], copyright (2007) National Academy of Sciences USA and 
Refs [43,46].  (D) Relationship between the single-channel conductance of CFTR and mean 
body temperature in endothermic vertebrates.  Values of mean body temperature are from Refs 
[60-62] and single-channel conductance from Refs [38-44,52].  The continuous line is the fit of 
a first-order regression to the data (r2 = 0.51). 
 



